Vertical: HealthcareBase Year: 2018
Market Size (2018)
$655.90M
Projected (2025)
$969.60M
CAGR (2016–2025)
5.7%
Key Players
7+
Spectral computed tomography (CT) is also known as dual-energy CT (DECT). It is an advanced form of computed tomography extensively used in x-ray scanning techniques. Spectral computed tomography is an advanced medical imaging device, which helps in the differentiation and characterization of tissues through the high quality of X-ray images. Spectral computed tomography (CT) contains two different energy spectra which provide concise images based on material density. The key advantage of dual-energy CT over single energy CT is that it is possible to use computer algorithms to generate a precise result, which is not possible in single energy CT.
The Spectral Computed Tomography CT Market market is projected to grow at a CAGR of 5.7% from 2016 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe scope of the global spectral computed tomography (CT) market study includes the market size analysis and a detailed analysis of the manufacturers’ products and strategies. The market has been segmented based on application, end user, and region.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global spectral computed tomography (CT) market is characterized by the presence of global, regional, and local vendors. The market is highly competitive with all players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive and growing market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional, and foreign players with small market shares also have a presence. The international players may strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share. Vendors with better technical and financial resources could develop innovative products. Therefore, vendors must develop new technologies and stay abreast of emerging technologies that could affect the continuing competitiveness of their treatment lines in the market.
General Electric Company (GE) is the parent company of GE Healthcare. GE Healthcare is a leading provider of medical imaging, monitoring, bio-manufacturing, and cell and gene therapy technologies and holds a significant position in the market. The company enables precision health in diagnostics, therapeutics, and monitoring through intelligent devices, data analytics, applications, and services. It has over 100 years of experience in the healthcare industry and helps improve outcomes more efficiently for patients, healthcare providers, researchers, and life science companies around the world. It has over four million imaging, mobile diagnostic, and monitoring units installed globally.
Bargaining Power of Suppliers
The suppliers in the global spectral computed tomography (CT) market are manufacturers of diagnostic imaging devices and technology platform developers. There are few suppliers present in the global spectral computed tomography (CT) market. Switching cost of these suppliers is high due to the high level of differentiation in intense competition. Additionally, research and development cost required for the development of software is quite high. Moreover, suppliers are likely to enter into long term partnerships with the healthcare providers and involved in more than one projects with the same client. Due to the increasing demand for cost-effective and efficient spectral computed tomography (CT), major companies are focusing on the emerging markets, due to the availability of a large number of customers.
Moreover, a smaller number of suppliers are there to cater to the needs of the customers, which lead to intense competition between the existing suppliers. However, the development of easy to use the software is a tough task, and software should provide accurate information regarding diagnosis. Hence, healthcare providers are selective about suppliers. Due to this, the overall bargaining power of suppliers in the global spectral computed tomography (CT) market is moderate to high.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global spectral computed tomography (CT) market. The market has many buyers and a limited number of spectral computed tomography (CT) providers to cater to the need of the buyers. However, spectral computed tomography (CT) is specialized and play an important role in healthcare services management, and the buyers of the spectral computed tomography (CT) are moderately inclined towards quality platforms developed by trusted companies. As the technology platforms and software are used for diagnosis purpose and highly specialized; hence, limited client substitutes are available in the market. Also, most of the buyers are healthcare providers, and they are likely to enter into the long-term agreements with the spectral computed tomography (CT) manufacturers for uninterrupted service. Moreover, they can exert pressure on the manufacturers due to the intense rivalry in the market, which is responsible for the increased bargaining power of buyers.
Threat of New Entrants
The threat of new entrants is moderate in the global spectral computed tomography (CT) market. Any company trying to develop diagnostic imaging devices is required to accept or abide by the mandatory regulatory standards. However, the budget required for the development of the diagnostic imaging devices platform is high as compared to other industries. Diagnostic imaging devices are specialized and developed to be used for the collection and sharing of patient data with ease. Moreover, the majority of the customers are using technology platforms developed by trusted providers, and they are likely to prefer established brands over new market player due to quality concerns and to maintain the quality of the final product, which does not comfort the new entrants to enter the market easily.
Threat of Substitutes
The threat of substitutes in the global spectral computed tomography (CT) market is moderate to high. Diagnostic imaging devices play an important role in the systematic gathering of data from different sources. There are several options available in the market to serve the need of the customers and which are responsible for increasing the threat of substitute. Many companies are developing systems which are compatible with different modalities and applications.
Additionally, the increasing research and development activities and demand for efficient technology platforms are likely to provide new substitutes to the medical image management. Also, the high degree of customization decreases the threat of substitutes. The overall threat of substitutes in the global diagnostic imaging devices is moderate to high.
Intensity of Rivalry
The rivalry in the global spectral computed tomography (CT) market is moderate to high. The limited number of customers and product launches by major players increases the intensity of rivalry in the market. The market is growing with a prominent growth rate and likely to provide opportunities for major players to expand their geographical boundaries which will initiate cutthroat competition between major players to capture maximum market share in the emerging markets. Players are engaged in developing a process to lower their development cost to increase profitability and to overcome the competition. Moreover, they are also developing advanced platforms for differentiating their brand from their competitors.
Market estimates by geography (2025)
InsightAsia Pacific leads with $532.20M by 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Asia Pacific | $314.80M | $420.50M | $532.20M | 6.0% | 55% |
| Americas | $130.20M | $171.90M | $215.50M | 5.8% | 22% |
| Europe | $112.20M | $148.80M | $187.20M | 5.9% | 19% |
| Middle East and Africa | $29.30M | $32.60M | $34.70M | 1.9% | 4% |
| Total | $586.50M | $773.80M | $969.60M | 5.7% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$969.60M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Oncology | $355.20M | 6.0% | 37% |
| Cardiology | $221.10M | 6.2% | 23% |
| Musculoskeletal Disorders | $185.70M | 5.8% | 19% |
| Gastrointestinal Diseases | $153.70M | 5.8% | 16% |
| Others | $53.90M | 2.7% | 6% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Spectral Computed Tomography CT Market covering market dynamics, competitive landscape, and strategic outlook.
The Spectral Computed Tomography CT Market market is projected to reach $969.60M by 2025, growing at 5.7% CAGR. The Oncology segment holds the largest share.
Spectral computed tomography (CT) also known as dual-energy CT (DECT) is an advanced form of computed tomography widely used in x-ray scanning technique. Spectral computed tomography is an advanced medical imaging device, which helps in the differentiation and characterization of tissues through the high quality of X-ray images. Spectral computed tomography (CT) contains two different energy spectra to provide concise images on the basis of material density. The key advantage of dual-energy CT over single energy CT is that in dual-energy CT, it is possible to use computer algorithms to generate a precise result which is not possible in single energy CT.
The major key factors driving the market growth are increasing spending on the healthcare IT sector, technological advancements in the diagnostics sector and increasing demand for diagnostic devices for precise imaging enhances the market growth. Also, the growing prevalence of cardiovascular and neurological diseases across the globe increase the demand for spectral computed tomography (CT) devices. However, factors such as high cost compared to conventional CT scan machines, availability of alternatives CT scan devices, and the less awareness about the products among the radiologists may hamper the market growth.
The increasing technological advancements in diagnostic imaging devices are considered to grow the market in the coming years. Computed tomography, radiography, and fluoroscopy are different forms of medical imaging devices used in x-ray scanning by hospitals.
The increasing adaption of IT in medical devices to improve the quality of the product is a major step in the medical imaging industry. Medical image management is closely associated with diagnosis services and is an essential part of the healthcare IT sector. The healthcare IT sector plays an important role in the medical device industry by improving the efficiency of products at every level of use.
Through secondary studies, it is found that healthcare IT spending has been increased rapidly in recent years, which is expected to drive the growth of the spectral CT market and its related services during the forecast period of 2019 to 2025. The rise in investment to improve and advance healthcare IT by global market leaders such as Siemens Healthcare, GE Healthcare, Koninklijke Philips N.V. shows a potential scope for the growth of the medical imaging industry. The increasing acceptance and approval of the cloud technology in medical image devices provide easy storage and sharing of huge data. Also, increasing mergers and acquisitions between healthcare and IT companies accelerate market growth. Moreover, developed economies such as the US, UK, and Japan are contributing to enhancing market growth by the adoption of cloud technology in medical imaging.
The need for healthcare IT services is growing exponentially in emerging economies to overcome the critical issues of medication errors, to provide efficient patient care, and to meet rising need to curtail escalating healthcare costs. There is a growing demand for healthcare IT solutions such as medical imaging systems for picture archiving and communication systems (PACS) in developing countries. Emerging markets, mainly India, Spain, and others, pose a large growth potential in the global spectral computed tomography (CT) market mainly owing to increasing occurrences of chronic diseases such as cancer, and various heart diseases.
The hospitals, clinics, and many other healthcare facilities are highly dependent on medical imaging systems, and it requires additional applications/software to be installed in the systems, which increases the expenses. The systems also require the installation of other hardware devices that may raise the cost of the system. The high cost of spectral computed tomography may act as a barrier in both developed and developing countries and creates a lot of problems for new manufacturers to enter into this market. According to the Association for the Advancement of Medical Instrumentation 2016 report, spectral computed tomography scanners cost between USD1.6 and USD 2.2 million. Furthermore, maintenance charges also contribute to the high cost.
Thus, the high cost of medical imaging devices is likely to restrain the growth of the global spectral computed tomography (CT) market during the forecast period.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 105 companies operating in the Spectral Computed Tomography CT Market market, including revenue, employee count, and market positioning where available.
Showing 105 of 105 companies
Company Headquarters: Shenyang, Liaoning China Founded: 1998 Workforce: 10,001 Company Working: Neusoft Corporation (Neusoft) deals in providing innovative information technology-enabled solutions and services to meet the unmet demands of its customers. Neusoft was established at Northeastern University, China. It has ten software research and development bases, eight regional headquarters, and a comprehensive marketing and service network covering over 60 cities across China, as well as subsidiaries in the US, Europe, Japan, the Middle East, and South America. It helps industry customers establish best practices in business development and management.
Company Headquarters: US Founded: 1937 Workforce: ~13,000 Company Address: PerkinElmer Inc, 331 Treble Cove Rd, Billerica, Massachusetts, 01862 US. Contact Details: Product Sales: California (1-408-232-0653); Puerto Rico (1-787 783 3067); Connecticut (1-203-905-4600); Investor Relation Contact (ir@perkinelmer.com Tel: (781) 663 6900, Address: 940 Winter Street, Waltham, MA 02451 US) Company Working: PerkinElmer Inc (PerkinElmer) is largely engaged in providing solutions to diagnostics, delivery, and analytical solutions markets. The company deals in creating innovative solutions for better and fast diagnosis of various health issues worldwide. It pioneers in scientific technologies for better detection, imaging, and informatics. The company serves its customers in over 150 countries. PerkinElmer has nearly 3,500 patents active and operates in clinical research, life sciences, food, environmental, and industrial markets.
Company Headquarters: Founded: 1998 Workforce: 377,000 Company Working: Siemens Healthcare Private Limited is the distinctly managed healthcare business of Siemens AG empowering healthcare providers globally to meet their current challenges and to outperform in their respective environments. Siemens is a leader in medical technology. It is continuously updating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging in laboratory diagnostics and molecular medicine. It is dynamically developing its digital health and enterprise services.
Company Headquarters: Christchurch, New Zealand Founded: 2007 Workforce: 50 Company Working: MARS Bioimaging Ltd (MBI) is a medical device company involved in innovating, manufacturing, and marketing imaging systems for medical diagnosis. The company offers a spectral computed tomography (CT) system used in medical diagnosis applications. MBI also offers MARS Micro-CT scanner, which is an innovative machine that consists of an x-ray source and camera system sideways with computer hardware, customized image reconstruction, electronics, and viewing software for use in biomedical research.
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
